Literature DB >> 21444285

Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin.

Cindy Tofthagen1, R Denise McAllister, Susan C McMillan.   

Abstract

Neuropathic side effects are commonly reported in patients receiving oxaliplatin, but little is known about the characteristics of peripheral neuropathy in this patient population. The purpose of this descriptive study was to explore the prevalence of neuropathic symptoms in patients with colorectal cancer receiving oxaliplatin as well as to explore symptom severity, distress, frequency, and neuropathic interference with activities. Thirty-three patients receiving oxaliplatin at two outpatient facilities completed the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool. Data were analyzed using descriptive statistics. Cold sensitivity, tingling in the hands, and numbness in the hands were the most prevalent neuropathic symptoms, and cold sensitivity, nerve pain, and trouble with balance were the most severe symptoms. Trouble with balance, muscle or joint aches, and neuropathic pain were the most distressing symptoms, and numbness in the fingers and hands and in the toes and feet were the most frequent symptoms. Patients reported that neuropathic symptoms interfered with numerous activities. Oncology nurses can use this information to help educate patients and families about potential side effects of oxaliplatin and to coordinate the care of patients with peripheral neuropathy using a symptom-focused, multidisciplinary approach.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21444285     DOI: 10.1188/11.CJON.182-188

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  22 in total

Review 1.  Emerging trends in understanding chemotherapy-induced peripheral neuropathy.

Authors:  Jérémy Ferrier; Vanessa Pereira; Jérome Busserolles; Nicolas Authier; David Balayssac
Journal:  Curr Pain Headache Rep       Date:  2013-10

Review 2.  Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment.

Authors:  Nathan P Staff; Guido Cavaletti; Badrul Islam; Maryam Lustberg; Dimitri Psimaras; Stefano Tamburin
Journal:  J Peripher Nerv Syst       Date:  2019-10       Impact factor: 3.494

3.  Reliability testing of oxaliplatin-associated neurotoxicity questionnaire (OANQ), a pilot study.

Authors:  E Gustafsson; E Litström; C Berterö; J Drott
Journal:  Support Care Cancer       Date:  2015-07-04       Impact factor: 3.603

4.  Evaluation of the Efficacy of the Three-Component Health Care Management Program HEWCOT in Colorectal Cancer Patients Receiving Chemotherapy.

Authors:  Iknur Aydin Avci; Birsen Altay; Figen Cavusoglu; Ayse Cal; Nuran Mumcu; Dilek Celik Eren; Ozge Oz; Alaattin Altin; Ozden Karaoglanoglu; Ayse Buberci
Journal:  J Cancer Educ       Date:  2020-04       Impact factor: 2.037

Review 5.  Mechanisms, Predictors, and Challenges in Assessing and Managing Painful Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Grace A Kanzawa-Lee; Robert Knoerl; Clare Donohoe; Celia M Bridges; Ellen M Lavoie Smith
Journal:  Semin Oncol Nurs       Date:  2019-04-30       Impact factor: 2.315

6.  Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).

Authors:  Deirdre R Pachman; Rui Qin; Drew K Seisler; Ellen M L Smith; Andreas S Beutler; Lauren E Ta; Jacqueline M Lafky; Nina D Wagner-Johnston; Kathryn J Ruddy; Shaker Dakhil; Nathan P Staff; Axel Grothey; Charles L Loprinzi
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

7.  Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.

Authors:  Ying Guo; Desiree Jones; J Lynn Palmer; Arthur Forman; Shaker R Dakhil; Maria R Velasco; Matthias Weiss; Paul Gilman; G M Mills; Stephen J Noga; Cathy Eng; Michael J Overman; Michael J Fisch
Journal:  Support Care Cancer       Date:  2013-12-22       Impact factor: 3.603

8.  Spinal astrocyte gap junctions contribute to oxaliplatin-induced mechanical hypersensitivity.

Authors:  Seo-Yeon Yoon; Caleb R Robinson; Haijun Zhang; Patrick M Dougherty
Journal:  J Pain       Date:  2013-02       Impact factor: 5.820

9.  The trajectory of neurotoxic side effects' impact on daily life: a qualitative study.

Authors:  Jenny Drott; Hans Starkhammar; Karin Kjellgren; Carina Berterö
Journal:  Support Care Cancer       Date:  2016-03-19       Impact factor: 3.603

10.  Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer.

Authors:  Xin Shelley Wang; Qiuling Shi; Patrick M Dougherty; Cathy Eng; Tito R Mendoza; Loretta A Williams; David R Fogelman; Charles S Cleeland
Journal:  Oncology       Date:  2016-02-17       Impact factor: 2.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.